earn report chang price
var ying rang outcom product
organ revenu beat well st vs st
oncolog gross order grew impress organ growth
gross margin beat st estim bp
ep omx guidanc lower mid-
point respect tough comp fiscal
halcyon new order deceler sequenti vs
could affect gm expans go forward
apac slowdown organ basi due tough comp
interest sever reason headlin number
great double-digit organ revenue print driven product
revenu growth anoth strong oncolog order print seemingli
bode well recal fy end sept stock
current trade consensu number expens
 one would think stock multipl bake high
singl digit top-line growth doubl digit ep growth issu
struggl two front margin revenu outlook
lower current year om target larg due increment tariff impact
impli gm rang assum mon impact
tariff think could bp assum
mix similar variabl hing manag
commentari potenti exclud cancer therapi tariff list
happen could potenti second
product rev grown ytd order growth averag
long term think product revenu grow in-lin
order backlog current diverg product revenue growth
order impli potenti low singl digit product revenue growth
declin depend mix believ comp issu
tariff headwind weigh ep growth model
ep st impli growth given
potenti slowdown earn growth lower pt
slightli reaffirm under-perform rate
continu next page
pleas see analyst certif import disclosur page report evercor isi affili seek busi
compani cover research report investor awar firm may conflict interest could affect object
report investor consid report singl factor make invest decis
cash equival mm
cfo mm mm ytd
consid tax reform import tariff
revenu growth
flow op mm previou
oper margin
adjust ep lower
fx headwind similar
 scale revenu
order revenue cc basi
instal base grew unit
servic revenu grew expect grow overtim
order total new order
high interest halcyon platform
emerg market increment unit
global market share growth share gain emea spain
china japan
growth sea australia
effect tax rate
adjust effect tax rate excl transit new legisl
mm share repurchas share
evercor isi medic suppli devicesvarian medic system stat million except per share data fy end septemb organ gp less op less ep share inc net inc price-to-earnings prem disc juli
valuat methodolog base mix discount cash flow analysi rel valuat multipl
upsid risk halcyon contribut earlier expect result share gain revenu acceler robust
margin expans driven improv mix stronger expect ramp proton therapi medium term
articl articl
time dissemin juli et
analyst vijay kumar alina levchuk primarili respons prepar research report attest follow
view opinion render research report reflect person view subject compani issuer part
research analyst compens directli relat specif recommend view research report
